Plasma Atrial Natriuretic Peptide in Essential Hypertension after Treatment with Irbesartan

Panagiotis Kotridis From the Departments of Second Cardiology, Pharmacology and Biochemistry, Medical School, Aristotle University of Thesssaloniki, Greece

Basile Kokkas From the Departments of Second Cardiology, Pharmacology and Biochemistry, Medical School, Aristotle University of Thesssaloniki, Greece

Michalis Karamouzis From the Departments of Second Cardiology, Pharmacology and Biochemistry, Medical School, Aristotle University of Thesssaloniki, Greece

George Sakadamis From the Departments of Second Cardiology, Pharmacology and Biochemistry, Medical School, Aristotle University of Thesssaloniki, Greece

Ioannis Kanonidis From the Departments of Second Cardiology, Pharmacology and Biochemistry, Medical School, Aristotle University of Thesssaloniki, Greece

George Dadous From the Departments of Second Cardiology, Pharmacology and Biochemistry, Medical School, Aristotle University of Thesssaloniki, Greece

Chrisoula Karantona From the Departments of Second Cardiology, Pharmacology and Biochemistry, Medical School, Aristotle University of Thesssaloniki, Greece

Olga Gouli From the Departments of Second Cardiology, Pharmacology and Biochemistry, Medical School, Aristotle University of Thesssaloniki, Greece

Joshef Karadoumanis From the Departments of Second Cardiology, Pharmacology and Biochemistry, Medical School, Aristotle University of Thesssaloniki, Greece

Pavlos C. Papadopoulos From the Departments of Second Cardiology, Pharmacology and Biochemistry, Medical School, Aristotle University of Thesssaloniki, Greece

Constantine L. Papadopoulos From the Departments of Second Cardiology, Pharmacology and Biochemistry, Medical School, Aristotle University of Thesssaloniki, Greece

show all

Abstract

The aim of this study was to evaluate the medium-term effects of the selective AT 1 -blocker irbesartan on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally in a daily dose of 300 mg for 30 days. Plasma ANP levels increased by 15.7% despite the drop in blood pressure and the slight decrease of atrial and ventricular diameters. These findings indicate that AT 1 -blockers like irbesartan exert part of their antihypertensive action by increasing ANP plasma levels.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Plasma Atrial Natriuretic Peptide in Essential Hypertension after Treatment with Irbesartan

Information for

Open access

Opportunities

Help and information

Plasma Atrial Natriuretic Peptide in Essential Hypertension after Treatment with Irbesartan

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature